The number of companies with Qin Medicine B License in Hengqin has increased to 9, and the clustering effect of the pharmaceutical industry is beginning to emerge.

Recently, the pharmaceutical industry in the Hengqin Guangdong-Macao in-depth cooperation zone (hereinafter referred to as the “Cooperation Zone”) has again brought good news: three companies, including Zhengqing Haiqin (Zhuhai Hengqin) Technology Co., Ltd., and Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., have successively obtained approval for the “Drug Manufacturing License” (Category B, hereinafter referred to as the “B Certificate”).

By now, the Cooperation Zone has 9 B Certificate drug manufacturing enterprises, with the number nearing that of Zhuhai city. The proportion of B Certificate enterprises in the province exceeds 7%. This indicates that the pharmaceutical industry ecosystem cluster under the “Hengqin R&D held + entrusted production in the Mainland” model has taken shape.

A B Certificate refers to the type of “Drug Manufacturing License” held by the marketing authorization holder for drugs manufactured on a contract/entrusted basis. Companies holding B Certificates are essentially “permits” that enable them, in accordance with the law, to engage in activities related to drug marketing authorization. They can entrust the drug manufacturing process to enterprises that comply with good drug manufacturing practice (quality management standards), while they focus on R&D, registration, quality control, and marketing and sales. This model strongly promotes the transformation of innovative drug development achievements, helps innovative enterprises grow efficiently, and is highly aligned with the Cooperation Zone’s characteristics of concentrated R&D resources and intensive, high-efficiency land use. It also helps guide companies to focus on the core R&D and innovation functions, break through the dependence on land space inherent in traditional manufacturing models, and attract end-to-end resources—including pharmaceutical R&D, marketing authorization, and sales supply—to accelerate their aggregation.

At present, among the 9 B Certificate enterprises, 5 have built laboratories in the Cooperation Zone, gradually forming a complete industrial chain of “R&D–registration–manufacturing–sales.” Their R&D and quality control capabilities continue to strengthen, achieving coordinated progress in “covering the baseline, ensuring safety, and promoting development.”

In recent years, the Cooperation Zone’s Bureau of Business and Commerce Services has consistently focused on enterprise needs, adhering to a proactive, front-positioned approach and providing precise services to safeguard the development of the pharmaceutical industry. During the key stage of enterprises applying for B Certificates, it provides full-process guidance and one-on-one targeted connections, helping enterprises obtain approvals efficiently. By organizing face-to-face exchange tea talks and conducting on-site visits to enterprises, it gains a deep understanding of companies’ development needs, promptly answers their difficult questions, and continuously strengthens policy guidance and professional support.

Next, the Cooperation Zone’s Bureau of Business and Commerce Services will continue to base itself on its functional responsibilities, focus on the core goal of enabling industries, precisely connect with enterprises’ development needs, and continuously optimize service measures and improve service effectiveness, so as to empower high-quality development of enterprises through high-quality services.

By｜Reporter Zhang Zhiyu

Photo｜Provided by the interviewee